BTL Expands EMSELLA Platform: New Health Canada License Enhances Intimate Wellness Solutions
BTL Expands EMSELLA Platform: New Health Canada License Enhances Intimate Wellness Solutions
On June 5, 2025, BTL, a recognized leader in non-invasive medical technology, declared significant advancements concerning its revolutionary EMSELLA® platform. This announcement comes with expanded Health Canada licenses that reinforce the company’s position in the realms of pelvic health and intimate wellness.
The EMSELLA platform, which has already received FDA approval and Health Canada licensing for treating urinary incontinence in both genders, has now been granted an additional Health Canada license. Notably, it has also secured CE-mark certification for its efficacy in enhancing sexual function among patients experiencing somatic sexual arousal disorders due to compromised pelvic floor muscles.
The Clinical Evidence
Supported by robust clinical data, EMSELLA is redefining non-invasive care practices focused on pelvic health and sexual function. Key findings from clinical studies are noteworthy:
- - A remarkable 76% improvement in sexual satisfaction and desire.
- - A 60% increase in the quality of orgasms.
- - A 37% enhancement in maintaining an erection during intercourse.
- - An impressive 48% boost in pelvic muscle endurance.
When juxtaposed with alternative modalities, EMSELLA stands out by proving to be seven times more effective than conventional pelvic floor muscle training. These statistics further validate the platform's significance in personal health restoration procedures.
Expert Insights
David Chmel, CEO of BTL North America, expresses enthusiasm regarding EMSELLA’s advantages: “The platform continues to exceed expectations—not just in addressing incontinence but also in restoring confidence and overall quality of life.” With these newly acquired clearances and positive clinical outcomes, the validity of EMSELLA’s impactful results resonates strongly with both medical providers and patients alike.
In support of this innovation, Dr. Shari Caplan, a renowned expert in functional and integrative health, notes, “We’re witnessing a total transformation in the approach to pelvic and sexual health. Patients are achieving results that were once thought feasible only through surgical intervention or extensive therapy.” She emphasizes that for urinary control and sexual wellness in both men and women, EMSELLA has become indispensable in contemporary medical practice.
A Growing Demand
As societal interest in intimate wellness treatments continues to surge, EMSELLA is uniquely positioned to address pressing and often neglected health issues. Unlike traditional methods, EMSELLA offers a non-invasive alternative that is accessible and comfortable for patients. This is particularly important in an age where discussions surrounding intimate health have become more prevalent but still remain sensitive topics.
Conclusion
For those curious to explore the capabilities of EMSELLA, further information is available at www.emsella.com. Understanding these advancements highlights BTL’s commitment to leading in medical device innovations that prioritize patient wellness and elevate the standard of care in intimate health.
About BTL
Founded in 1993, BTL is a global force in medical devices, delivering innovative care solutions across various fields, including dermatology, orthopedics, med spas, and gynecology. With over 350 patents and a talented team of more than 580 engineers, BTL leverages technology and scientific advancements for superior medical applications. Their diverse product line includes notable names like EMSCULPT NEO®, EMFACE®, EXION™, and, of course, EMSELLA®.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.